Neurocognitive Disorders Clinical Trials
2 recruiting trials for Neurocognitive Disorders. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Neurocognitive Disorders clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Advanced Technology & Communications (1), Sunnybrook Health Sciences Centre (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is ATNC MDD-V1 (Real TMS + Real Cog) (device, 1 trial), followed by ATNC MDD-V1 (Sham TMS + Real Cog), ATNC BN-V1.
Track Neurocognitive Disorders trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.
rTMS for Apathy Clinical Trial
Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Neurocognitive Disorders, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Neurocognitive Disorders, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Neurocognitive Disorders, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.